NO861553L - Angiogen faktor og fremgangsmaate for frembringelse av angiogenese. - Google Patents

Angiogen faktor og fremgangsmaate for frembringelse av angiogenese.

Info

Publication number: NO861553L
Authority: NO; Norway
Prior art keywords: preparation; angiogenic; lipid; neovascularization; tissue
Prior art date: 1984-08-20

Application number

NO861553A

Other languages

English (en)

Norwegian (no)

Inventor

Nicholas Catsimpoolas

Harry Goldsmith

Original Assignee

Univ Boston

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1984-08-20

Filing date

1986-04-18

Publication date

1986-04-18

1986-04-18 Application filed by Univ Boston filed Critical Univ Boston

1986-04-18 Publication of NO861553L publication Critical patent/NO861553L/no

Links

238000000034 method Methods 0.000 title claims description 37
230000033115 angiogenesis Effects 0.000 title claims description 14
238000002360 preparation method Methods 0.000 claims description 100
150000002632 lipids Chemical class 0.000 claims description 84
230000002491 angiogenic effect Effects 0.000 claims description 58
206010029113 Neovascularisation Diseases 0.000 claims description 35
210000001519 tissue Anatomy 0.000 claims description 27
210000002747 omentum Anatomy 0.000 claims description 23
210000004204 blood vessel Anatomy 0.000 claims description 22
238000002347 injection Methods 0.000 claims description 22
239000007924 injection Substances 0.000 claims description 22
230000017531 blood circulation Effects 0.000 claims description 20
239000003960 organic solvent Substances 0.000 claims description 17
241000282326 Felis catus Species 0.000 claims description 16
238000000605 extraction Methods 0.000 claims description 15
210000004087 cornea Anatomy 0.000 claims description 14
230000000694 effects Effects 0.000 claims description 14
239000002904 solvent Substances 0.000 claims description 10
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 8
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 8
229910052799 carbon Inorganic materials 0.000 claims description 8
229910052739 hydrogen Inorganic materials 0.000 claims description 8
239000001257 hydrogen Substances 0.000 claims description 8
229910052760 oxygen Inorganic materials 0.000 claims description 8
239000001301 oxygen Substances 0.000 claims description 8
206010017076 Fracture Diseases 0.000 claims description 6
206010052428 Wound Diseases 0.000 claims description 6
208000027418 Wounds and injury Diseases 0.000 claims description 6
230000035876 healing Effects 0.000 claims description 6
230000002792 vascular Effects 0.000 claims description 6
208000010392 Bone Fractures Diseases 0.000 claims description 5
210000004369 blood Anatomy 0.000 claims description 5
239000008280 blood Substances 0.000 claims description 5
125000004432 carbon atom Chemical group C* 0.000 claims description 5
238000001727 in vivo Methods 0.000 claims description 5
230000001965 increasing effect Effects 0.000 claims description 5
208000010125 myocardial infarction Diseases 0.000 claims description 5
210000005003 heart tissue Anatomy 0.000 claims description 4
206010062542 Arterial insufficiency Diseases 0.000 claims description 3
208000001778 Coronary Occlusion Diseases 0.000 claims description 3
206010061216 Infarction Diseases 0.000 claims description 3
241000124008 Mammalia Species 0.000 claims description 3
230000004071 biological effect Effects 0.000 claims description 3
230000002490 cerebral effect Effects 0.000 claims description 3
230000007574 infarction Effects 0.000 claims description 3
230000009885 systemic effect Effects 0.000 claims description 3
241000283973 Oryctolagus cuniculus Species 0.000 claims description 2
210000003205 muscle Anatomy 0.000 claims 10
230000003966 vascular damage Effects 0.000 claims 4
125000001931 aliphatic group Chemical group 0.000 claims 3
210000000988 bone and bone Anatomy 0.000 claims 3
208000025865 Ulcer Diseases 0.000 claims 2
230000001133 acceleration Effects 0.000 claims 2
210000005013 brain tissue Anatomy 0.000 claims 2
230000006378 damage Effects 0.000 claims 2
239000003814 drug Substances 0.000 claims 2
229940079593 drug Drugs 0.000 claims 2
210000002027 skeletal muscle Anatomy 0.000 claims 2
231100000397 ulcer Toxicity 0.000 claims 2
WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical group OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 claims 1
238000004519 manufacturing process Methods 0.000 claims 1
230000002285 radioactive effect Effects 0.000 claims 1
238000000926 separation method Methods 0.000 claims 1
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 52
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 37
210000002414 leg Anatomy 0.000 description 32
239000002870 angiogenesis inducing agent Substances 0.000 description 20
238000001356 surgical procedure Methods 0.000 description 15
230000015572 biosynthetic process Effects 0.000 description 14
239000002953 phosphate buffered saline Substances 0.000 description 12
239000000203 mixture Substances 0.000 description 9
239000000284 extract Substances 0.000 description 7
108090000623 proteins and genes Proteins 0.000 description 7
102000004169 proteins and genes Human genes 0.000 description 7
241001465754 Metazoa Species 0.000 description 5
238000002474 experimental method Methods 0.000 description 5
-1 methanol lipid Chemical class 0.000 description 5
239000000126 substance Substances 0.000 description 5
TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 description 4
206010061218 Inflammation Diseases 0.000 description 4
206010028980 Neoplasm Diseases 0.000 description 4
229910021626 Tin(II) chloride Inorganic materials 0.000 description 4
238000011161 development Methods 0.000 description 4
230000018109 developmental process Effects 0.000 description 4
238000005194 fractionation Methods 0.000 description 4
230000004054 inflammatory process Effects 0.000 description 4
239000007788 liquid Substances 0.000 description 4
230000003389 potentiating effect Effects 0.000 description 4
239000001119 stannous chloride Substances 0.000 description 4
235000011150 stannous chloride Nutrition 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
241000282412 Homo Species 0.000 description 3
241000276498 Pollachius virens Species 0.000 description 3
201000011510 cancer Diseases 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
238000010828 elution Methods 0.000 description 3
210000003743 erythrocyte Anatomy 0.000 description 3
210000003414 extremity Anatomy 0.000 description 3
210000001105 femoral artery Anatomy 0.000 description 3
230000012010 growth Effects 0.000 description 3
208000015181 infectious disease Diseases 0.000 description 3
239000000463 material Substances 0.000 description 3
239000008188 pellet Substances 0.000 description 3
229920001184 polypeptide Polymers 0.000 description 3
102000004196 processed proteins & peptides Human genes 0.000 description 3
108090000765 processed proteins & peptides Proteins 0.000 description 3
230000007998 vessel formation Effects 0.000 description 3
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
208000034657 Convalescence Diseases 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 description 2
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
208000032109 Transient ischaemic attack Diseases 0.000 description 2
150000001338 aliphatic hydrocarbons Chemical class 0.000 description 2
230000006427 angiogenic response Effects 0.000 description 2
239000007900 aqueous suspension Substances 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
230000004087 circulation Effects 0.000 description 2
238000010586 diagram Methods 0.000 description 2
230000005484 gravity Effects 0.000 description 2
238000010562 histological examination Methods 0.000 description 2
238000010255 intramuscular injection Methods 0.000 description 2
239000007927 intramuscular injection Substances 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
238000010253 intravenous injection Methods 0.000 description 2
238000011835 investigation Methods 0.000 description 2
238000002955 isolation Methods 0.000 description 2
229960003299 ketamine Drugs 0.000 description 2
230000008569 process Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
230000004044 response Effects 0.000 description 2
238000002390 rotary evaporation Methods 0.000 description 2
239000000741 silica gel Substances 0.000 description 2
229910002027 silica gel Inorganic materials 0.000 description 2
210000000278 spinal cord Anatomy 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
201000010875 transient cerebral ischemia Diseases 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
230000029663 wound healing Effects 0.000 description 2
206010002383 Angina Pectoris Diseases 0.000 description 1
102000008076 Angiogenic Proteins Human genes 0.000 description 1
108010074415 Angiogenic Proteins Proteins 0.000 description 1
206010006803 Burns third degree Diseases 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
241000557626 Corvus corax Species 0.000 description 1
GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 1
206010012689 Diabetic retinopathy Diseases 0.000 description 1
206010015150 Erythema Diseases 0.000 description 1
239000004367 Lipase Substances 0.000 description 1
102000004882 Lipase Human genes 0.000 description 1
108090001060 Lipase Proteins 0.000 description 1
NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
102000007474 Multiprotein Complexes Human genes 0.000 description 1
108010085220 Multiprotein Complexes Proteins 0.000 description 1
101100005280 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cat-3 gene Proteins 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
241000283977 Oryctolagus Species 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
241001111421 Pannus Species 0.000 description 1
208000018262 Peripheral vascular disease Diseases 0.000 description 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
210000003815 abdominal wall Anatomy 0.000 description 1
210000001789 adipocyte Anatomy 0.000 description 1
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
229910052921 ammonium sulfate Inorganic materials 0.000 description 1
235000011130 ammonium sulphate Nutrition 0.000 description 1
230000003872 anastomosis Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000006286 aqueous extract Substances 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
210000000617 arm Anatomy 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000002146 bilateral effect Effects 0.000 description 1
230000036770 blood supply Effects 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
210000004720 cerebrum Anatomy 0.000 description 1
239000002026 chloroform extract Substances 0.000 description 1
SKCNIGRBPJIUBQ-UHFFFAOYSA-N chloroform;ethyl acetate Chemical compound ClC(Cl)Cl.CCOC(C)=O SKCNIGRBPJIUBQ-UHFFFAOYSA-N 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
210000003683 corneal stroma Anatomy 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
235000021438 curry Nutrition 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
231100000321 erythema Toxicity 0.000 description 1
239000012530 fluid Substances 0.000 description 1
210000001733 follicular fluid Anatomy 0.000 description 1
210000004013 groin Anatomy 0.000 description 1
239000008241 heterogeneous mixture Substances 0.000 description 1
238000002513 implantation Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
208000014674 injury Diseases 0.000 description 1
230000010354 integration Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
210000003127 knee Anatomy 0.000 description 1
238000002350 laparotomy Methods 0.000 description 1
235000019421 lipase Nutrition 0.000 description 1
ZADHKSJXSZBQFB-HHHXNRCGSA-N lipid fragment Chemical compound CC(C)CCCCCCCCCCCC[C@@H](C)CCCCCCCC(C)C ZADHKSJXSZBQFB-HHHXNRCGSA-N 0.000 description 1
238000004811 liquid chromatography Methods 0.000 description 1
230000007774 longterm Effects 0.000 description 1
238000001819 mass spectrum Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
210000004379 membrane Anatomy 0.000 description 1
239000012528 membrane Substances 0.000 description 1
238000003808 methanol extraction Methods 0.000 description 1
239000000401 methanolic extract Substances 0.000 description 1
XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 1
210000003657 middle cerebral artery Anatomy 0.000 description 1
238000002156 mixing Methods 0.000 description 1
210000004165 myocardium Anatomy 0.000 description 1
JFRJCQJVFMHZOO-QZHHGCDDSA-N n-(2-aminoethyl)-2-[4-[[2-[4-[[9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purin-6-yl]amino]phenyl]acetyl]amino]phenyl]acetamide Chemical compound C1=CC(CC(=O)NCCN)=CC=C1NC(=O)CC(C=C1)=CC=C1NC1=NC=NC2=C1N=CN2[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 JFRJCQJVFMHZOO-QZHHGCDDSA-N 0.000 description 1
230000009251 neurologic dysfunction Effects 0.000 description 1
208000015015 neurological dysfunction Diseases 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
238000012633 nuclear imaging Methods 0.000 description 1
201000005111 ocular hyperemia Diseases 0.000 description 1
230000021368 organ growth Effects 0.000 description 1
230000008520 organization Effects 0.000 description 1
230000020477 pH reduction Effects 0.000 description 1
238000012856 packing Methods 0.000 description 1
206010033675 panniculitis Diseases 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
239000011574 phosphorus Substances 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
239000000902 placebo Substances 0.000 description 1
210000002826 placenta Anatomy 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000012545 processing Methods 0.000 description 1
239000002296 pyrolytic carbon Substances 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000008439 repair process Effects 0.000 description 1
210000001525 retina Anatomy 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
229940048086 sodium pyrophosphate Drugs 0.000 description 1
UGTZMIPZNRIWHX-UHFFFAOYSA-K sodium trimetaphosphate Chemical compound [Na+].[Na+].[Na+].[O-]P1(=O)OP([O-])(=O)OP([O-])(=O)O1 UGTZMIPZNRIWHX-UHFFFAOYSA-K 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000011877 solvent mixture Substances 0.000 description 1
210000004003 subcutaneous fat Anatomy 0.000 description 1
210000004304 subcutaneous tissue Anatomy 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
239000000725 suspension Substances 0.000 description 1
210000001179 synovial fluid Anatomy 0.000 description 1
229940056501 technetium 99m Drugs 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
230000008467 tissue growth Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
230000008733 trauma Effects 0.000 description 1
210000005166 vasculature Anatomy 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
230000000007 visual effect Effects 0.000 description 1
210000004127 vitreous body Anatomy 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Zoology (AREA)
Physiology (AREA)
Biotechnology (AREA)
Cell Biology (AREA)
Developmental Biology & Embryology (AREA)
Nutrition Science (AREA)
Biomedical Technology (AREA)
Virology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Compositions Of Oxide Ceramics (AREA)
Inorganic Insulating Materials (AREA)
Peptides Or Proteins (AREA)

NO861553A 1984-08-20 1986-04-18 Angiogen faktor og fremgangsmaate for frembringelse av angiogenese. NO861553L (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US06/642,624 US4699788A (en)	1984-08-20	1984-08-20	Angiogenic factor methods of extraction and method for producing angiogenesis

Publications (1)

Publication Number	Publication Date
NO861553L true NO861553L (no)	1986-04-18

Family

ID=24577348

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO861553A NO861553L (no)	1984-08-20	1986-04-18	Angiogen faktor og fremgangsmaate for frembringelse av angiogenese.

Country Status (12)

Country	Link
US (1)	US4699788A (fr)
EP (1)	EP0191804A1 (fr)
JP (1)	JPS62500026A (fr)
KR (1)	KR870700359A (fr)
AU (1)	AU584914B2 (fr)
BR (1)	BR8506887A (fr)
CA (1)	CA1261258A (fr)
DK (1)	DK179086A (fr)
FI (1)	FI861654A7 (fr)
NO (1)	NO861553L (fr)
RO (1)	RO94021B (fr)
WO (1)	WO1986001111A1 (fr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4897464A (en) *	1985-04-17	1990-01-30	President And Fellows Of Harvard College	Purified protein having angiogenic activity and methods of preparation
US4710490A (en) *	1985-10-01	1987-12-01	Angio Medical Corporation	Compositions containing ganglioside molecules with enhanced angiogenic activity
US4767746A (en) *	1985-12-04	1988-08-30	Trustees Of Boston University	Method for enhancement of healing of epithelial wounds in mammals
US4990333A (en) *	1985-12-20	1991-02-05	Angio Medical Corporation	Method for healing bone damage
US4879114A (en) *	1985-12-20	1989-11-07	Angio-Medical Corporation	Lipids from omentum and methods for cosmetic use
US4778787A (en) *	1985-12-20	1988-10-18	Trustees Of Boston University	Method for treatment of angina and myocardial infarctions with omental lipids
EP0274547A1 (fr) *	1986-12-18	1988-07-20	Trustees Of Boston University	Méthode pour augmenter la guérison de blessures épithéliales chez les mammifères
IL84864A0 (en) *	1986-12-31	1988-06-30	Univ Boston	Composition for promoting hair growth containing omental lipids and process for promoting hair growth utilizing the same
GB8708009D0 (en) *	1987-04-03	1987-05-07	Clayton Found Res	Injectable soft tissue augmentation materials
US4952403A (en) *	1987-06-19	1990-08-28	President And Fellows Of Harvard College	Implants for the promotion of healing of meniscal tissue
US4952404A (en) *	1987-06-19	1990-08-28	President And Fellows Of Harvard College	Promotion of healing of meniscal tissue
US4853219A (en) *	1987-08-06	1989-08-01	President And Fellows Of Harvard College	Antibodies to angiogenin: immunotherapeutic agents
US4940730A (en) *	1987-10-29	1990-07-10	Takeda Chemical Industries, Ltd.	Angiogenesis enhancer
US4879312A (en) *	1988-03-07	1989-11-07	Angio Medical Corporation	Method for enhancing or provoking angiogenesis using angiogenically active omega-3 polyunsaturated fatty acids
IE891173L (en) *	1988-04-18	1989-10-18	Univ Utrecht	Composition for promoting hair growth in androgenetic¹alopecia and method thereof
WO1996001641A1 (fr) *	1994-07-08	1996-01-25	Sulzer Medizinaltechnik Ag	Procede de fabrication de materiaux pour greffe
US5733884A (en) *	1995-11-07	1998-03-31	Nestec Ltd.	Enteral formulation designed for optimized wound healing
DE69733815T2 (de)	1996-02-15	2006-06-08	Biosense Webster, Inc., Diamond Bar	Sonde zur exkavation
US6443974B1 (en)	1996-07-28	2002-09-03	Biosense, Inc.	Electromagnetic cardiac biostimulation
AU3911097A (en) *	1996-08-08	1998-02-25	Localmed, Inc.	Transmural drug delivery method and apparatus
WO1998019626A2 (fr) *	1996-11-05	1998-05-14	Localmed, Inc.	Procede et dispositif d'administration intraluminale continue de substances bioactives
ES2255155T3 (es)	1998-02-05	2006-06-16	Biosense Webster, Inc.	Dispositivo para la administracion intracardiaca de farmacos.
US20030113303A1 (en) *	1998-02-05	2003-06-19	Yitzhack Schwartz	Homing of embryonic stem cells to a target zone in tissue using active therapeutics or substances
US20030129750A1 (en) *	1998-02-05	2003-07-10	Yitzhack Schwartz	Homing of donor cells to a target zone in tissue using active therapeutics or substances
CA2329010A1 (fr) *	1998-04-17	1999-10-28	Angiogenix Incorporated	Facteurs angiogeniques therapeutiques et procedes d'utilisation
US6211157B1 (en)	1998-05-01	2001-04-03	Sulzer Biologics, Inc.	Protein mixtures to induce therapeutic angiogenesis
US6992066B2 (en)	1998-10-16	2006-01-31	Zimmer Orthobiologics, Inc.	Povidone-containing carriers for polypeptide growth factors
US7087577B2 (en) *	1998-10-16	2006-08-08	Zimmer Orthobiologies, Inc.	Method of promoting natural bypass
US9597395B2 (en)	2001-12-07	2017-03-21	Cytori Therapeutics, Inc.	Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions
US7771716B2 (en)	2001-12-07	2010-08-10	Cytori Therapeutics, Inc.	Methods of using regenerative cells in the treatment of musculoskeletal disorders
US7514075B2 (en)	2001-12-07	2009-04-07	Cytori Therapeutics, Inc.	Systems and methods for separating and concentrating adipose derived stem cells from tissue
US7651684B2 (en)	2001-12-07	2010-01-26	Cytori Therapeutics, Inc.	Methods of using adipose tissue-derived cells in augmenting autologous fat transfer
US7595043B2 (en)	2001-12-07	2009-09-29	Cytori Therapeutics, Inc.	Method for processing and using adipose-derived stem cells
US20050048035A1 (en)	2001-12-07	2005-03-03	Fraser John K.	Methods of using regenerative cells in the treatment of stroke and related diseases and disorders
KR100930139B1 (ko)	2001-12-07	2009-12-07	사이토리 테라퓨틱스, 인크.	처리된 리포애스퍼레이트 세포로 환자를 치료하기 위한시스템 및 방법
US20050095228A1 (en)	2001-12-07	2005-05-05	Fraser John K.	Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders
US7585670B2 (en)	2001-12-07	2009-09-08	Cytori Therapeutics, Inc.	Automated methods for isolating and using clinically safe adipose derived regenerative cells
US7232802B2 (en) *	2001-12-21	2007-06-19	Zimmer Orthobiologics, Inc.	Compositions and methods for promoting myocardial and peripheral angiogenesis
US7241874B2 (en) *	2002-06-26	2007-07-10	Zimmer Ortho Biologics, Inc.	Rapid isolation of osteoinductive protein mixtures from mammalian bone tissue
US7622562B2 (en)	2002-06-26	2009-11-24	Zimmer Orthobiologics, Inc.	Rapid isolation of osteoinductive protein mixtures from mammalian bone tissue
EP2252305A4 (fr) *	2008-01-26	2013-05-01	Surinder Singh Saini	Épiploon et son utilisation
WO2010021993A1 (fr)	2008-08-19	2010-02-25	Cytori Therapeutics, Inc.	Procédés d'utilisation de cellules issues du tissu adipeux dans le traitement du système lymphatique et d'une maladie maligne
AU2010242780B2 (en)	2009-05-01	2016-04-21	Puregraft Llc	Systems, methods and compositions for optimizing tissue and cell enriched grafts
US10071122B2 (en) *	2011-03-25	2018-09-11	Cooperlabs Limited	Heat-extracted omentum extracts, compositions, methods of preparing and uses thereof
IL250881A0 (en)	2017-03-01	2017-06-29	Pali Nazir	A process of instant creation of artificial bone tissue
IL257853A (en)	2018-03-04	2019-03-31	Pali Nazir	Process for building artificial multifunctional injectable filler

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4229532A (en) *	1978-12-29	1980-10-21	Monsanto Company	Production of tumor angiogenesis factor by cell culture
US4209587A (en) *	1978-12-29	1980-06-24	Monsanto Company	Production of tumor angiogenesis factor by cell culture
US4210719A (en) *	1978-12-29	1980-07-01	Monsanto Company	Production of tumor angiogenesis factor by cell culture
US4229531A (en) *	1978-12-29	1980-10-21	Monsanto Company	Production of tumor angiogenesis factor by cell culture
US4225670A (en) *	1978-12-29	1980-09-30	Monsanto Company	Production of tumor angiogenesis factor by cell culture
US4210718A (en) *	1978-12-29	1980-07-01	Monsanto Company	Production of tumor angiogenesis factor by cell culture
US4217412A (en) *	1979-04-25	1980-08-12	President And Fellows Of Harvard College	Production of tumor angiogenesis factor by cell culture
US4273871A (en) *	1980-03-03	1981-06-16	Monsanto Company	Production of angiogenic factor by cell culture
US4268629A (en) *	1980-03-03	1981-05-19	Monsanto Company	Production of angiogenic factor by cell culture
CA1168980A (fr) *	1980-04-17	1984-06-12	Rolf Schafer	Compositions cicatrisantes
ZA833446B (en) *	1982-05-28	1984-02-29	Solco Basel Ag	Process for the preparation of cell-and tissue-regenerating substances
US4529590A (en) *	1982-12-27	1985-07-16	Leveen Robert F	Production of angiogenetic factor

1984
- 1984-08-20 US US06/642,624 patent/US4699788A/en not_active Expired - Fee Related
1985
- 1985-08-01 JP JP60503442A patent/JPS62500026A/ja active Pending
- 1985-08-01 AU AU46387/85A patent/AU584914B2/en not_active Ceased
- 1985-08-01 WO PCT/US1985/001445 patent/WO1986001111A1/fr not_active Ceased
- 1985-08-01 EP EP85903953A patent/EP0191804A1/fr not_active Withdrawn
- 1985-08-01 BR BR8506887A patent/BR8506887A/pt unknown
- 1985-08-01 FI FI861654A patent/FI861654A7/fi not_active Application Discontinuation
- 1985-08-19 CA CA000488992A patent/CA1261258A/fr not_active Expired
1986
- 1986-04-18 DK DK179086A patent/DK179086A/da not_active Application Discontinuation
- 1986-04-18 NO NO861553A patent/NO861553L/no unknown
- 1986-04-19 KR KR860700224A patent/KR870700359A/ko not_active Ceased
- 1986-04-21 RO RO123075A patent/RO94021B/ro unknown

Also Published As

Publication number	Publication date
JPS62500026A (ja)	1987-01-08
CA1261258A (fr)	1989-09-26
DK179086D0 (da)	1986-04-18
AU4638785A (en)	1986-03-07
KR870700359A (ko)	1987-12-28
BR8506887A (pt)	1986-12-09
FI861654A0 (fi)	1986-04-18
US4699788A (en)	1987-10-13
EP0191804A1 (fr)	1986-08-27
FI861654L (fi)	1986-04-18
WO1986001111A1 (fr)	1986-02-27
RO94021B (ro)	1988-03-31
FI861654A7 (fi)	1986-04-18
AU584914B2 (en)	1989-06-08
RO94021A (fr)	1988-03-30
DK179086A (da)	1986-04-18

Publication	Publication Date	Title
NO861553L (no)	1986-04-18	Angiogen faktor og fremgangsmaate for frembringelse av angiogenese.
Goldsmith et al.	1984	Lipid angiogenic factor from omentum
Jiang et al.	2020	Three-dimensional bioprinting collagen/silk fibroin scaffold combined with neural stem cells promotes nerve regeneration after spinal cord injury
Wang et al.	2022	Injectable hyaluronic acid hydrogel loaded with BMSC and NGF for traumatic brain injury treatment
Yang et al.	2023	A hyaluronic acid granular hydrogel nerve guidance conduit promotes regeneration and functional recovery of injured sciatic nerves in rats
Stookey et al.	1922	Surgical and mechanical treatment of peripheral nerves
NO873504L (no)	1987-10-19	Fremgangsmaate for behandling av angina og myokardialinfarkter med omentallipider.
Jiang et al.	2023	Decellularized-disc based allograft and xenograft prosthesis for the long-term precise reconstruction of temporomandibular joint disc
JPS63502035A (ja)	1988-08-11	骨の損傷を治療する方法と組成物
AU2017245981B2 (en)	2020-07-23	Polyethylene glycol-modified angiogenesis inhibitor HM-1 and application thereof
Schoene et al.	1970	Hereditary sensory neuropathy: A clinical and ultrastructural study
Lu et al.	2010	Effect of Astragalus membranaceus in rats on peripheral nerve regeneration: in vitro and in vivo studies
Gao et al.	2024	Wnt-3a improves functional recovery after spinal cord injury by regulating the inflammatory and apoptotic response in rats via wnt/β-catenin signaling pathway
CN101627990A (zh)	2010-01-20	葛根素在制备p2x3介导疼痛/神经系统疾病药物中的应用
Wang et al.	2020	The effects of triptolide on the cellular activity of cryopreserved rat sciatic nerves and nerve regeneration after allotransplantation
Stockwell	1965	Lipid in the matrix of ageing articular cartilage
CN102716464A (zh)	2012-10-10	短肽在制备治疗血管增生性眼科疾病药物中的应用
Zhang et al.	2023	Chitosan-based conduits with different inner diameters at both ends combined with modified formula radix hedysari promote nerve transposition repair
CN108434166B (zh)	2021-06-22	一种血塞通药物组合物及其制备方法、制剂与应用
US11788058B2 (en)	2023-10-17	Protein-modified PLGA microsphere and tissue-engineered nerve constructed therewith
CN102716470B (zh)	2015-02-04	一种治疗周围神经损伤的药物组合物
Barski et al.	1997	Autologous connective tissue bars as vehicles for the administration of growth-influencing substances to the brain
CN108420804A (zh)	2018-08-21	一种载黄芪甲苷聚已内酯膜及其制备方法和应用
Fioretti et al.	1984	Monitoring of hematoporphyrin injected in humans and clinical prospects of its use in gynecologic oncology
Young et al.	1987	Modulation of human lymphocyte proliferation by normal bovine vitreous.